| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2078348 | Cell Stem Cell | 2007 | 5 Pages |
Abstract
Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Jean C.Y. Wang,